VTVT vTv Therapeutics

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

HIGH POINT, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the H.C. Wainwright “HCW@Home” Series, being held virtually on Thursday, June 12, 2025.

Conference details are as follows:

H.C. Wainwright “HCW@Home with vTv Therapeutics”

Format: Fireside Chat

Moderator: Emily Bodnar, Director, H.C. Wainwright

vTv Therapeutics Speakers:

  • Paul Sekhri, Chairman of the Board, President & Chief Executive Officer
  • Thomas Strack, MD, Chief Medical Officer
  • Carmen Valcarce, Ph.D., Executive Vice President, Chief Scientific Officer
  • Michael Tung, MD, MBA, Chief Financial Officer

Date: Thursday, June 12, 2025

Time: 10:00 AM ET

Webcast Link: Register

The webcast of the event will be accessible from News & Events page of the vTv website.

About vTv Therapeutics

vTv Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv's clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules into different indications for chronic diseases. Learn more at  or follow the company on  or .

Investor Contact

John Fraunces

LifeSci Advisors, LLC

917-355-2395

Media Contact

Caren Begun

TellMed Strategies

201-396-8551



EN
11/06/2025

Underlying

VTVTvTv Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on vTv Therapeutics

 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics Announces New Appointments to its Scientific Advisory...

vTv Therapeutics Announces New Appointments to its Scientific Advisory Board Board to offer guidance on clinical development of cadisegliatin for type 1 diabetes as company has initiated Phase 3 trials HIGH POINT, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, today announced the appointment of Alfonso Galderisi, MD, PhD, Mark Evans, MD, Chantal Mathieu, MD, PhD, and Klara Klein, MD, PhD, to its Scientific Advisory Board (SAB). The SAB, composed of internationally recognize...

October 9, 2025 1 EN
 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61s...

vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting Company to share new independent research on TTP-RA, vTv’s oral RAGE antagonist HIGH POINT, N.C., Sept. 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced that the company will present information on two of its investigational small molecules for type 1 diabetes (T1D) at the INNODIA Symposium during the European Association for the Study of Diabetes (EASD) 61st Annual Meeting. INNODIA is an international non-for-profit organizatio...

September 15, 2025 1 EN
 PRESS RELEASE
Free
VTVT vTv Therapeutic...

UPDATE -- vTv Therapeutics to Participate in Upcoming September Invest...

UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor conferences: H.C. Wainwright 27th Annual Global Investment ConferenceDate:Tuesday, September 9, 2025Format:1x1 Investo...

September 3, 2025 1 EN
 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics to Participate in Upcoming September Investor Confere...

vTv Therapeutics to Participate in Upcoming September Investor Conferences HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor conferences: H.C. Wainwright 27th Annual Global Investment ConferenceDate:Tuesday, September 9, 2025Format:1x1 Investor Meetings...

September 3, 2025 1 EN
 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics Announces $80 Million Private Placement with Leading ...

vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund Proceeds to fund ongoing CATT1 Phase 3 trial and continued development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes Topline data from CATT1 Phase 3 trial on track for second half 2026 HIGH POINT, N.C., Sept. 02, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, poten...

September 2, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch